CYP2C9 and ovarian carcinoma: Regarding CYP2C9 polymorphisms, this particular genotype of CYP2C9 rs1057910 was associated with a reduced response rate, worse progression of the disease, and a lower overall survival rate in ovarian cancer patients treated with platinum drugs [105].